Table 1 Summary of drugs tested for in vitro and in vivo potentiation in combination with electroporation pulses

Bleomycin

Yes; 100–5000-fold [1, 17, 18, 26–28]

Yes

Cisplatin

Yes; 1.8–12.2-fold [17, 18, 28, 29]

Yes [28–30]

Calcium

Yes; more hundred-fold [31, 32]

Yes [31]

Netropsin

Yes; 200-fold [1]

–

Carboplatin

Yes; 1.6–13-fold [17, 18, 27, 29]

–

2-N-methyl-9-hydroxy-ellipticinium (NMHE)

Yes; 4-fold [1]

–

Vincristine

Yes; 1.3–3.4-fold [18]

–

ActiNomycin D

Yes; 2–3-fold [1]

–

Cytarabine

Yes; 2-fold [18]

–

Oxaliplatin

Yes [29]

–

Platinum (II) complex 3P-SK

Yes [29]

Yes [29]

Platinum (II) complex PtAMP

Yes [29]

–

Mitomycin C

Yes but low; 1.3–1.4-fold [18, 33]

–

Vinblastine

Yes but low; 1.1–1.3-fold [18]

–

5-fluorouracil

No or low; 1.25-fold [18, 26]

–

Paclitaxel

No or low; 1.3-fold [17, 18]

–

Doxorubicin

No or low; 0.67–2-fold [17, 18]

–

Nimustine hydrochloride (ACNU)

No [27]

–

Methotrexate

No [1]

–

9-OH-ellipticine

No [1]

–

Didemnin B

No [1]

–

Melphalan

No [1]

–

Mithramycin

No [1]

–

Taxotere

No [1]

–

DauNorubicin

No [17]

–

Adriamycin

No [32]

No [28]

Etoposide

No or ND [17, 18, 27]

–

Ancitabine

ND [18]

–

Gemcitabine

ND [18]

–